EXPERIMENTAL RESEARCH
Comparative study of the efficacy of bevacizumab
and rose bengal photodynamic therapy for treatment of corneal neovascularization
1
Ophthalmic Unit, National Institute of Laser Enhanced Sciences, Cairo University, Egypt
2
Department of Vision Science, Biophysics and Laser Science Unit, Research Institute of Ophthalmology, Giza, Egypt
3
Physics Department, Biophysics Branch, Faculty of Science, Al-Azhar University (Boys), Cairo, Egypt
Submission date: 2020-09-03
Final revision date: 2021-01-07
Acceptance date: 2021-01-24
Publication date: 2021-05-05
Arch Med Sci Civil Dis 2021;6(1):22-30
KEYWORDS
corneal neovascularizationbevacizumabphotodynamic therapyprotein secondary structureoxidative stress
TOPICS
ABSTRACT
Introduction:
To compare the efficacy of bevacizumab and rose bengal photodynamic therapy (RB-PDT) in the treatment of corneal neovascularization (CNV).
Material and methods:
The study design included the induction of CNV by suture placement in three groups of New Zealand rabbits: (1) a group with CNV without any treatment; (2) a group treated with subconjunctival injection of bevacizumab (25 mg/eye); (3) a group treated with intravenous injection of rose bengal and exposed to 532 nm photodynamic therapy. For 4 weeks, the animals were followed up by slit-lamp to analyze the extent of CNV, evaluate the corneal protein secondary structure, and determine the oxidative stress index (OSI).
Results:
After 4 weeks, traces of neovascularization were observed only in the bevacizumab treated group with grade 0.5. The contents of -helix and -sheet were 17% and 61% in CNV, 32%, and 46% in bevacizumab and 40% and 36% in RB-PDT groups vs. 43% and 35% for the control group. Moreover, the percentage changes in the total oxidative status (TOS) for CNV, bevacizumab and RB-PDT groups were 97.1%, 14.6%, and 1.0%, respectively, with respect to the control. The total antioxidant status (TAC) showed no significant changes (p > 0.05) for both treated groups. The percentage of changes in OSI was 15.9% and 1.3% in bevacizumab, and RB-PDT treated groups compared with the control group.
Conclusions:
Both modes of treatment were effective in the regression of CNV, but RB-PDT was more efficient than bevacizumab by improving the corneal protein secondary structure and the oxidative stress.
To compare the efficacy of bevacizumab and rose bengal photodynamic therapy (RB-PDT) in the treatment of corneal neovascularization (CNV).
Material and methods:
The study design included the induction of CNV by suture placement in three groups of New Zealand rabbits: (1) a group with CNV without any treatment; (2) a group treated with subconjunctival injection of bevacizumab (25 mg/eye); (3) a group treated with intravenous injection of rose bengal and exposed to 532 nm photodynamic therapy. For 4 weeks, the animals were followed up by slit-lamp to analyze the extent of CNV, evaluate the corneal protein secondary structure, and determine the oxidative stress index (OSI).
Results:
After 4 weeks, traces of neovascularization were observed only in the bevacizumab treated group with grade 0.5. The contents of -helix and -sheet were 17% and 61% in CNV, 32%, and 46% in bevacizumab and 40% and 36% in RB-PDT groups vs. 43% and 35% for the control group. Moreover, the percentage changes in the total oxidative status (TOS) for CNV, bevacizumab and RB-PDT groups were 97.1%, 14.6%, and 1.0%, respectively, with respect to the control. The total antioxidant status (TAC) showed no significant changes (p > 0.05) for both treated groups. The percentage of changes in OSI was 15.9% and 1.3% in bevacizumab, and RB-PDT treated groups compared with the control group.
Conclusions:
Both modes of treatment were effective in the regression of CNV, but RB-PDT was more efficient than bevacizumab by improving the corneal protein secondary structure and the oxidative stress.
REFERENCES (32)
1.
Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol 2001; 12: 242-9.
2.
Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing. Trans Am Ophthalmol Soc 2006; 104: 264-302.
3.
Epstein RJ, Stulting RD, Hendricks RL, Harris DM. Corneal neovascularization. Pathogenesis and inhibition. Cornea 1987; 6: 250-7.
4.
Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci 1996; 37: 2485-94.
5.
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
6.
Abdelkawi SA, Hassan AA. Evaluation of protein change and oxidative stress index after photodynamic therapy of corneal neovascularization. Gen Physiol Biophys 2012; 31: 449-55.
7.
Hou Y, Le VNH, Clahsen T, Schneider AC, Bock F, Cursiefen C. Photodynamic therapy leads to time-dependent regression of pathologic corneal (lymph) angiogenesis and promotes high-risk corneal allograft survival. Invest Ophthalmol Vis Sci 2017; 58: 5862-9.
8.
Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 2004; 82: 557-63.
9.
Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004; 38: 1258-64.
10.
Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695-705.
11.
Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006; 26: 279-84. .
12.
Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006; 142: 1054-6. .
13.
Pieramici DJ, Rabena MD. Anti-VEGF therapy: comparison of current and future agents. Eye 2008; 22: 1330-6.
14.
DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007; 125: 834-6.
15.
Kim, TI, Kim SW, Kim S, Kim T, Kim EK. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 2008; 27: 349-52. .
16.
Walter A. American Society of Cinical Oncology, Annual meeting and Rose Bengal: from a wool dye to a cancer therapy. Pharm Ther 2010; 35: 469-74.
17.
Norihiko Y. Vital staining for disorders of conjunctiva and lids. Atarashii Ganka 2012; 29: 1599-605.
18.
Ervin AM, Wojciechowski R, Schein O. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev 2017; 9: CD006775.
19.
Cursiefen C, Wenkel H, Martus P, et al. Impact of short-term versus long- term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol 2001; 239: 514-21.
20.
Acar BT, Halili E, Acar S. The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization. Int Ophthalmol 2013; 33: 507-13.
21.
Huang AJW, Watson BD, Hernandez E, Tseng SCG. Photothrombosis of corneal neovascularization by intravenous rose bengal and argon laser irradiation. Arch Ophthalmol 1988; 106: 680-5.
22.
Koracevic D, Koracevic G, Djordjevic V, Andrejevic S, Cosic V. Method for the measurement of antioxidant activity in human fluids. J Clin Pathol 2001; 54: 356-61.
24.
Demirbag R, Gur M, Yilmaz R, Kunt AS, Erel O, Andac MH. Influence of oxidative stress on the development of collateral circulation in total coronary occlusions. Int J Cardiol 2007; 116: 14-9.
25.
Khakshoor O, Nowick JS. Artificial b-sheets: chemical models of b-sheets. Curr Opin Chem Biol 2008; 12: 722-9.
26.
Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000; 41: 2514-22. .
27.
Watanabe M, Yano W, Kondo S, et al. Up-regulation of urokinase-type plasminogen activator in corneal epithelial cells induced by wounding. Invest Ophthalmol Vis Sci 2003; 44: 3332-8.
28.
Los M, Roodhart JML, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007; 12: 443-50.
29.
Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998; 39: 18-22.
30.
Panzarini E, Inguscio V, Fimia GM, Dini L. Rose Bengal acetate photodynamic therapy (RBAc-PDT) induces exposure and release of damage-associated molecular patterns (DAMPs) in human HeLa cells. PLoS One 2014; 9: e105778.
31.
Ferreira SM, Lerner SF, Brunzini R, Evelson PA, Llesuy SF. Oxidative stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol 2004; 137: 62-9.
32.
Koksal H, Kurban S. Total oxidant status, total antioxidant status, and paraoxonase and arylesterase activities during laparoscopic cholecystectomy. Clinics 2010; 65: 285-90.
| ISSN: | 2451-0637 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
